Rx Product News (June 2016)
Read about the new Rx Products featured in June.
Eli Lilly and Company
INDICATION: The FDA has approved Taltz (ixekizumab), a humanized interleukin-17A antagonist, for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The recommended dose is 160 mg (two 80-mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
DOSAGE FORM: Injection: 80-mg/mL solution in a single- dose prefilled autoinjector or a single-dose prefilled syringe
FOR MORE INFORMATION: taltz.com
VENCLEXTAMARKETED BY: AbbVie, Inc
INDICATION: The FDA has approved Venclexta (venetoclax), a BCL-2 inhibitor, for the treatment of patients with chronic lymphocytic leukemia with 17p deletion (as detected by an FDA-approved test), who have received at least 1 prior therapy. Venclexta should be initiated at 20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg.
DOSAGE FORM: Tablets: 10, 50, and 100 mg
FOR MORE INFORMATION: venclexta.com
DESCOVYMARKETED BY: Gilead Sciences, Inc
INDICATION: The FDA has approved Descovy (emtricitabine and tenofovir alafenamide), for use in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. The recommended dosage is 1 tablet once daily, with or without food, in patients 12 years and older with a body weight of at least 35 kg and a creatinine clearance greater than or equal to 30 mL per minute.
DOSAGE FORM: Tablets: 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide
FOR MORE INFORMATION: descovy.com
BEVESPI AEROSPHEREMARKETED BY: AstraZeneca
INDICATION: The FDA has approved Bevespi Aerosphere for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. The recommended dosage is 2 inhalations twice daily.
DOSAGE FORM: Inhalation aerosol: pressurized metered-dose inhaler containing a combination of glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol
FOR MORE INFORMATION: astrazeneca.com